Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The ROR1 data are sketchy, and lung toxicity clouds prospects.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
